158 related articles for article (PubMed ID: 19751286)
1. Columbia University's Axel patents: technology transfer and implications for the Bayh-Dole Act.
Colaianni A; Cook-Deegan R
Milbank Q; 2009 Sep; 87(3):683-715. PubMed ID: 19751286
[TBL] [Abstract][Full Text] [Related]
2. The Bayh-Dole Act at 40: Accomplishments, Challenges, and Possible Reforms.
Sarpatwari A; Kesselheim AS; Cook-Deegan R
J Health Polit Policy Law; 2022 Dec; 47(6):879-895. PubMed ID: 35877952
[TBL] [Abstract][Full Text] [Related]
3. University-based science and biotechnology products: defining the boundaries of intellectual property.
Kesselheim AS; Avorn J
JAMA; 2005 Feb; 293(7):850-4. PubMed ID: 15713775
[TBL] [Abstract][Full Text] [Related]
4. Academic Medical Centers as Innovation Ecosystems: Evolution of Industry Partnership Models Beyond the Bayh-Dole Act.
Silva PJ; Ramos KS
Acad Med; 2018 Aug; 93(8):1135-1141. PubMed ID: 29668523
[TBL] [Abstract][Full Text] [Related]
5. Patents and innovation in cancer therapeutics: lessons from CellPro.
Bar-Shalom A; Cook-Deegan R
Milbank Q; 2002; 80(4):637-76, iii-iv. PubMed ID: 12532643
[TBL] [Abstract][Full Text] [Related]
6. The Bayh-Dole Act turns 30.
Loise V; Stevens AJ
Sci Transl Med; 2010 Oct; 2(52):52cm27. PubMed ID: 20926832
[TBL] [Abstract][Full Text] [Related]
7. Intellectual property. University licensing and the Bayh-Dole Act.
Thursby JG; Thursby MC
Science; 2003 Aug; 301(5636):1052. PubMed ID: 12933996
[No Abstract] [Full Text] [Related]
8. Bayh-Dole: if we knew then what we know now.
Boettiger S; Bennett AB
Nat Biotechnol; 2006 Mar; 24(3):320-3. PubMed ID: 16525405
[No Abstract] [Full Text] [Related]
9. Lessons from Bayh-Dole.
Sampat BN
Nature; 2010 Dec; 468(7325):755-6. PubMed ID: 21150971
[No Abstract] [Full Text] [Related]
10. Patent and license pearls and pitfalls for taking an idea to the marketplace.
Mukharji I
J Investig Med; 2011 Jun; 59(5):758-61. PubMed ID: 21441827
[TBL] [Abstract][Full Text] [Related]
11. Why did universities start patenting? Institution-building and the road to the Bayh-Dole Act.
Berman EP
Soc Stud Sci; 2008 Dec; 38(6):835-71. PubMed ID: 19227798
[TBL] [Abstract][Full Text] [Related]
12. Technology transfer at US universities: seeking public benefit from the results of basic research.
Goodwin CD
Technol Health Care; 1996 Sep; 4(3):323-30. PubMed ID: 8931243
[TBL] [Abstract][Full Text] [Related]
13. Medical technology transfer: the inventor's perspective.
Marks LA
Biomed Instrum Technol; 1991; 25(1):35-41. PubMed ID: 2004192
[TBL] [Abstract][Full Text] [Related]
14. Do March-In Rights Ensure Access to Medical Products Arising From Federally Funded Research? A Qualitative Study.
Treasure CL; Avorn J; Kesselheim AS
Milbank Q; 2015 Dec; 93(4):761-87. PubMed ID: 26626985
[TBL] [Abstract][Full Text] [Related]
15. Global biotech expansion taking cues from Bayh-Dole.
Howard K
Nat Biotechnol; 2004 Jul; 22(7):919-20. PubMed ID: 15259190
[No Abstract] [Full Text] [Related]
16. Patenting and licensing of university-based genetic inventions--a view from experience at Stanford University's Office of Technology Licensing.
Leute K
Community Genet; 2005; 8(4):217-22. PubMed ID: 16244475
[TBL] [Abstract][Full Text] [Related]
17. Intellectual property and biotechnology: the U.S. internal experience--Part I.
Brody B
Kennedy Inst Ethics J; 2006 Mar; 16(1):1-37. PubMed ID: 16770885
[TBL] [Abstract][Full Text] [Related]
18. Research and the Bayh-Dole Act.
Reczek PR
Science; 2004 Jan; 303(5654):40. PubMed ID: 14704412
[No Abstract] [Full Text] [Related]
19. Using the written description requirement to limit broad patent scope, allow competition, and encourage innovation in biotechnology.
Mull WC
Health Matrix Clevel; 2004; 14(2):393-435. PubMed ID: 15503695
[TBL] [Abstract][Full Text] [Related]
20. Biotechs sue Columbia over fourth Axel patent.
Howard K
Nat Biotechnol; 2003 Sep; 21(9):955-6. PubMed ID: 12949538
[No Abstract] [Full Text] [Related]
[Next] [New Search]
